论文部分内容阅读
目的探讨4种药物治疗急性心肌梗死所产生的经济效果。方法选择64例急性心肌梗死患者,随机平分为A、B、C、D四组,在传统治疗的基础上,分别采用尿激酶、普伐他汀钠、胺碘酮与倍他乐克治疗。结果 A组的费用为8656元,B组的费用为4569元,C组的费用为6853元,D组费用为2132元。A组的疗效明显好于其他三组,其他三组间差异无统计学意义。D组的药物经济学效果最好。结论倍他乐克为最佳治疗方案,值得临床推广。
Objective To investigate the economic effects of four kinds of drugs in the treatment of acute myocardial infarction. Methods Sixty-four patients with acute myocardial infarction were randomly divided into four groups: A, B, C and D. On the basis of traditional treatment, urokinase, pravastatin sodium, amiodarone and metoprolol were used respectively. Results A group costs 8656 yuan, B group costs 4569 yuan, C group costs 6853 yuan, D group costs 2132 yuan. The efficacy of group A was significantly better than the other three groups, the other three groups showed no significant difference. Group D has the best pharmacoeconomic results. Conclusion Betaloc is the best treatment option and is worthy of clinical promotion.